{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010647","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.553128+00:00","generated_at":"2026-05-17T17:09:39.115251+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Collegium Q2 revenue $188M (+29% YoY); raises 2025 guidance; authorizes $150M buyback","bullets":["Record quarterly product revenue $188.0M, up 29% YoY; GAAP EPS $0.34 diluted; adjusted EPS $1.68.","Jornay PM net revenue $32.6M, prescriptions up 23% YoY; full-year Jornay PM guidance raised to $140-145M.","Pain portfolio revenue $155.4M (+7% YoY) with Belbuca $52.6M, Xtampza $52.6M, Nucynta $46.4M.","Raised FY2025 revenue guidance to $745-760M and adjusted EBITDA to $440-455M; cash $222.2M.","Board authorized $150M share repurchase through Dec 2026; completed $25M ASR in July."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010647","json":"https://secwatch.observer/filing/0001558370-25-010647.json","markdown":"https://secwatch.observer/filing/0001558370-25-010647.md","text":"https://secwatch.observer/filing/0001558370-25-010647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000155837025010647/0001558370-25-010647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000155837025010647/coll-20250807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:09:39.115251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}